ArticleCancer science2019

Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors.

Yuichi Ando et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.